New Delhi, April 4 -- : Minister of Science and Technology, Jitendra Singh, flagged India's limited domestic insulin manufacturing capacity as a critical gap, even as he positioned the country to play a larger role in addressing looming global shortages and affordability concerns in diabetes care.
The remarks came during a meeting with International Diabetes Federation President-elect Niti Pall, who is currently on a visit to India. The two discussed the need to scale up indigenous production of biosimilar insulin and expand capabilities in diabetes-related biomanufacturing.
Singh acknowledged that while India has established strengths in pharmaceuticals and medical devices, insulin production remains relatively limited. He pointed to ong...